Thanks captain obvious.😂
However, with no DCVax approval (with NICE reimbursement), they will have lost a big future revenue source. Because Advent is private, we have no idea of accurate sales figures, clients, profits, or debt. As a subsidiary of NWBO, they will now also carry the burden of NWBO losses, expenses and debt as well as their own.
I smell a reverse split and much more dilution ahead. Even if an approval was granted, they still have to run ped. trials, and hope for NICE reimbursement (which is highly unlikely bc of the cost). Also, a sales and marketing team is necessary and the launch will take many months. NICE will not give out an extra $150K (on top of SOC costs) for a vaccine that is obviously questionable, at best - based on peer reviews and the very long MHRA process.
It's fun to watch this reality show in real time, and I am glad I am not invested, which also makes me more objective. Nothing worse than being emotionally attached to a stock, it clouds your thinking.
GL
Market Data 
Markets 
AI
